sodium oxybate ER

targets

all catalysts(0)

nothing on the calendar yet

News(5)

• Takeda’s narcolepsy nod opens orexin doors
  Orzeyful is the first orexin agonist cleared by the FDA, and is the first narcolepsy therapy that addresses the full host of disease symptoms. It is "likely to reshape the treatment paradigm” for t…
  biospace · 5d ago
• STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
  The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be used to treat other conditions.
  stat · 6d ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 7d ago
• Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
  Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
  biopharma_dive · 1mo ago
• Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
  Plus, news from Vistagen, Enterprise Therapeutics, Cerevance and Memento Medicines. 😴 Alkermes’ narcolepsy drug succeeds in Phase 3 study: The company’s drug Lumryz, approved in 2023 for narcoleps…
  endpoints · 3mo ago